Core Points - BeiGene announced a royalty purchase agreement with Royalty Pharma, involving a payment of $885 million at closing [1][2] - The agreement grants Royalty Pharma rights to a significant portion of the royalties from the sales of the monoclonal antibody Imdelltra (Tarlatamab) outside of China [2] - BeiGene has the option to sell additional royalty rights to Royalty Pharma for up to $65 million until August 25, 2026, based on certain conditions [2] Financial Details - Royalty Pharma will pay $885 million to BeiGene Switzerland upon closing of the agreement [2] - The royalties are based on a tiered percentage of net revenues from Imdelltra sales outside of China [2] - If annual net revenues from Imdelltra exceed $1.5 billion, BeiGene will share a portion of the royalties with Royalty Pharma [2]